PL3893924T3 - Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania - Google Patents

Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania

Info

Publication number
PL3893924T3
PL3893924T3 PL19832737.1T PL19832737T PL3893924T3 PL 3893924 T3 PL3893924 T3 PL 3893924T3 PL 19832737 T PL19832737 T PL 19832737T PL 3893924 T3 PL3893924 T3 PL 3893924T3
Authority
PL
Poland
Prior art keywords
antibodies
methods
complement factor
human complement
human
Prior art date
Application number
PL19832737.1T
Other languages
English (en)
Inventor
Christophe Blanchetot
Hans De Haard
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of PL3893924T3 publication Critical patent/PL3893924T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
PL19832737.1T 2018-12-13 2019-12-13 Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania PL3893924T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Publications (1)

Publication Number Publication Date
PL3893924T3 true PL3893924T3 (pl) 2025-01-13

Family

ID=69143627

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19832737.1T PL3893924T3 (pl) 2018-12-13 2019-12-13 Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania

Country Status (21)

Country Link
US (4) US11161900B2 (pl)
EP (2) EP4375297A3 (pl)
JP (3) JP7110491B2 (pl)
KR (2) KR102774146B1 (pl)
CN (2) CN113260375B (pl)
AU (3) AU2019397614B2 (pl)
BR (1) BR112021011107A2 (pl)
CA (1) CA3119655A1 (pl)
DK (1) DK3893924T3 (pl)
EA (1) EA202191658A1 (pl)
ES (1) ES2991894T3 (pl)
FI (1) FI3893924T3 (pl)
HU (1) HUE068993T2 (pl)
IL (2) IL319975A (pl)
LT (1) LT3893924T (pl)
MX (2) MX2021006864A (pl)
PL (1) PL3893924T3 (pl)
PT (1) PT3893924T (pl)
SG (1) SG11202105195PA (pl)
WO (1) WO2020121282A1 (pl)
ZA (1) ZA202407097B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998468B2 (en) * 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
US9206257B2 (en) * 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
US9944717B2 (en) * 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
RS61351B1 (sr) * 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
WO2015089368A2 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
AU2016355206A1 (en) * 2015-11-19 2018-05-24 Abbvie Stemcentrx Llc Novel anti-EMR2 antibodies and methods of use
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
MA53248A (fr) * 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
RU2018130525A (ru) 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
WO2017196960A1 (en) 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
WO2018107109A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
WO2018193427A1 (en) * 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3078971A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
PL3893924T3 (pl) 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Also Published As

Publication number Publication date
HUE068993T2 (hu) 2025-02-28
IL319975A (en) 2025-05-01
JP7611191B2 (ja) 2025-01-09
KR102774146B1 (ko) 2025-02-26
JP7110491B2 (ja) 2022-08-01
JP2022160479A (ja) 2022-10-19
PT3893924T (pt) 2024-10-09
IL283916B1 (en) 2025-05-01
US11708403B2 (en) 2023-07-25
JP2024160274A (ja) 2024-11-13
US20220119509A1 (en) 2022-04-21
AU2022287637B2 (en) 2025-07-17
IL283916B2 (en) 2025-09-01
IL283916A (en) 2021-07-29
AU2019397614A1 (en) 2021-06-03
ZA202407097B (en) 2026-04-29
MX2021006864A (es) 2021-07-02
AU2025252632A1 (en) 2025-11-06
ES2991894T3 (es) 2024-12-05
SG11202105195PA (en) 2021-06-29
US11591386B2 (en) 2023-02-28
MX2025010337A (es) 2025-10-01
DK3893924T3 (da) 2024-11-04
BR112021011107A2 (pt) 2021-12-14
US20220267424A1 (en) 2022-08-25
NZ776117A (en) 2024-07-26
EA202191658A1 (ru) 2021-11-03
AU2022287637A1 (en) 2023-02-02
EP4375297A3 (en) 2024-10-30
US11161900B2 (en) 2021-11-02
EP3893924B1 (en) 2024-08-21
EP3893924A1 (en) 2021-10-20
CN119371526A (zh) 2025-01-28
EP4375297A2 (en) 2024-05-29
KR20210100688A (ko) 2021-08-17
WO2020121282A1 (en) 2020-06-18
KR20250030005A (ko) 2025-03-05
LT3893924T (lt) 2024-10-10
JP2022512223A (ja) 2022-02-02
CN113260375B (zh) 2024-10-01
FI3893924T3 (fi) 2024-10-04
US20240002484A1 (en) 2024-01-04
CN113260375A (zh) 2021-08-13
US20200239554A1 (en) 2020-07-30
CA3119655A1 (en) 2020-06-18
AU2019397614B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
IL278821A (en) Anti-SIRPA antibodies and methods of using them
IL276731A (en) Antibodies against CD73 and methods of using them
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
ZA201907513B (en) Human antibodies to bet v 1 and methods of use thereof
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
PL3618863T3 (pl) Przeciwciała anty- tigit i sposoby ich zastosowania
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
SG11202105195PA (en) Antibodies to human complement factor c2b and methods of use
HUE065544T2 (hu) Emberi anti-rankl ellenanyagok készítményei és eljárások alkalmazásukra
IL287282A (en) Anti-mertk antibodies and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL290741A (en) Antibodies against cd-96 and methods of using them
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
SG11202105010UA (en) Antibodies to mucin-16 and methods of use thereof
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
SG11202011146TA (en) Drug-resistant immune cells and methods of use thereof
IL283884A (en) Antibodies against il-36 and methods of using them
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL288886A (en) Antibodies and methods of use
IL289905A (en) Anti-grp78 antibodies and the method of using them